Condition: Adrenocortical Carcinoma
Intervention: Drug: Cabozantinib-s-malate
Sponsor: Wuerzburg University Hospital
Not yet recruiting
Feeds
5989 items (5989 unread) in 74 feeds
Acinar Cell Carcinoma
(37 unread)
Acinic Cell Carcinoma
(46 unread)
Adenoid Cystic Carcinoma
(84 unread)
Adrenal Gland Cancer
(430 unread)
Ampulla Of Vater
(36 unread)
Anal Cancer
(701 unread)
Angiosarcoma
(97 unread)
Appendix Cancer
(79 unread)
Bile Duct Cancer
(731 unread)
Brain and CNS
(942 unread)
Carcinoid
(126 unread)
Endocrine/Neuroendocrine
(706 unread)
Gall Bladder Cancer
(131 unread)
Hemangioendothelioma
(33 unread)
Hepatoblastoma
(56 unread)
Pancreas
(52 unread)
Phyllodes
(38 unread)
PMP and Mucinous Tumors
(24 unread)
Rhabdomyosarcoma
(140 unread)
Sarcoma
(1500 unread)
Trial - Adrenal Cancer (21 unread)
-
Cabozantinib in Advanced Adrenocortical Carcinoma
Posted: August 2nd, 2018, 2:00pm GMT
-
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Participants With Stage I-III Adrenocortical Cancer With High Risk of Recurrence
Posted: July 11th, 2018, 2:00pm GMT
Conditions: ENSAT Stage I Adrenal Cortex Carcinoma; ENSAT Stage II Adrenal Cortex Carcinoma; ENSAT Stage III Adrenal Cortex Carcinoma
Interventions: Drug: Cisplatin; Drug: Etoposide; Drug: Mitotane; Procedure: Quality-of-Life Assessment
Sponsors: M.D. Anderson Cancer Center; Amercian Australian Asian Adrenal Alliance (A5); European Network for the Study of Adrenal Tumors (ENS@T)
Not yet recruiting -
A Trial Comparing Transversus Abdominis Plane Catheter Versus Epidural After Esophagectomy
Posted: June 27th, 2018, 2:00pm GMT
Conditions: Esophageal Cancer; Pain, Postoperative
Interventions: Procedure: Esophagectomy; Procedure: Transversus abdominis plane catheter; Procedure: Epidural
Sponsor: Swedish Medical Center
Recruiting -
Early Recovery Outcomes After Standardized Fast-track Whipples Procedure
Posted: June 21st, 2018, 2:00pm GMT
Condition: Pancreas Cancer
Intervention: Other: Complications to Whipples procedure
Sponsor: Eske Kvanner Aasvang
Recruiting -
Postoperative Pain Control With Lipossomic Extended Release Bupivacaine
Posted: June 18th, 2018, 2:00pm GMT
Conditions: Pain, Postoperative; Lung Cancer
Interventions: Drug: Bupivacaine liposome; Drug: Bupivacaine / Epinephrine
Sponsor: University of Tennessee Health Science Center
Recruiting -
Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and Prostvac-VF in Metastatic Hormone-Sensitive Prostate Cancer
Posted: May 22nd, 2018, 2:00pm GMT
Condition: Metastatic Hormone-Sensitive Prostate Cancer
Interventions: Biological: PROSTVAC-V; Biological: PROSTVAC-F; Drug: Nivolumab; Drug: Ipilimumab; Biological: Neoantigen DNA vaccine; Device: TriGrid Delivery System; Procedure: Tumor biopsy; Procedure: Peripheral blood; Procedure: Fecal samples
Sponsors: Washington University School of Medicine; Bristol-Myers Squibb
Not yet recruiting -
Circulating Tumor DNA Exposure in Peripheral Blood
Posted: May 7th, 2018, 2:00pm GMT
Conditions: Colorectal Cancer; Pancreatic Adenocarcinoma; Gastric Cancer; Hepatocellular Carcinoma; Non-small Cell Lung Cancer; Bladder Cancer; Melanoma; Ovarian Cancer; Adrenocortical Cancer; Breast Cancer; Other Cancer
Intervention:
Sponsor: Quantgene Inc.
Recruiting -
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
Posted: April 3rd, 2018, 2:00pm GMT
Condition: Solid Tumors
Interventions: Biological: Pembrolizumab; Drug: Standard of Care (SOC)
Sponsor: Merck Sharp & Dohme Corp.
Not yet recruiting -
Speeding Recovery From Pain and Opioid Use
Posted: January 3rd, 2018, 3:00pm GMT
Conditions: Pain, Postoperative; Breast Cancer; Opioid Use; Surgery
Interventions: Drug: Local infiltration of bupivacaine; Drug: Pectoralis Nerve block
Sponsor: Wake Forest University Health Sciences
Not yet recruiting -
Breast Cancer Screening: Digital Breast Tomosynthesis Versus Digital 2D Mammography
Posted: December 19th, 2017, 3:00pm GMT
Condition: Breast Cancer Screening
Interventions: Diagnostic Test: DBT+s2D; Diagnostic Test: 2D-FFDM
Sponsors: University Hospital Muenster; German Research Foundation
Recruiting -
Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors
Posted: November 7th, 2017, 3:00pm GMT
Conditions: Genitourinary Cancer; Adrenocortical Carcinoma; Non-urothelial Bladder; Non-urothelial Upper Tract; Penile Cancer; Non-adenocarcinoma Prostate Cancer; Refractory Germ-cell
Interventions: Drug: Ipilimumab; Drug: Nivolumab
Sponsors: Dana-Farber Cancer Institute; Bristol-Myers Squibb
Recruiting -
Over-the-scope Clips and Standard Treatments in Endoscopic Control of Acute Bleeding From Non-variceal Upper GI Causes
Posted: July 13th, 2017, 2:00pm GMT
Conditions: Acute Upper Gastrointestinal Bleeding; Tumor Bleeding
Interventions: Device: Over-the-scope Clips; Device: Hemo-clipping; Device: thermo-coagulation; Drug: Epinephrine
Sponsors: Chinese University of Hong Kong; Queen Mary Hospital, Hong Kong; The First Affiliated Hospital of Soochow University; Beijing Friendship Hospital
Recruiting -
A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer
Posted: May 24th, 2017, 2:00pm GMT
Conditions: Paraganglioma; Gastrointestinal Stromal Tumors; Carcinoma, Renal Cell; Renal Neoplasms; Pheochromocytoma
Intervention: Drug: SGI-110 (guadecitabine)
Sponsor: National Cancer Institute (NCI)
Recruiting -
Propranolol Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery
Posted: May 15th, 2017, 2:00pm GMT
Condition: Prostate Carcinoma
Interventions: Other: Laboratory Biomarker Analysis; Drug: Propranolol Hydrochloride; Other: Questionnaire Administration; Other: Survey Administration
Sponsors: Wake Forest University Health Sciences; National Cancer Institute (NCI)
Recruiting -
Familial Investigations of Childhood Cancer Predisposition
Posted: February 10th, 2017, 3:00pm GMT
Conditions: Acute Leukemia; Adenomatous Polyposis; Adrenocortical Carcinoma; AML; BAP1 Tumor Predisposition Syndrome; Carney Complex; Choroid Plexus Carcinoma; Constitutional Mismatch Repair Deficiency Syndrome; Diamond-Blackfan Anemia; DICER1 Syndrome; Dyskeratosis Congenita; Emberger Syndrome; Familial Acute Myeloid Leukemia; Familial Adenomatous Polyposis; Fanconi Anemia; Familial Cancer; Familial Wilms Tumor; Familial Neuroblastoma; GIST; Hereditary Breast and Ovarian Cancer; Hereditary Paraganglioma-Pheochromocytoma Syndrome; Hodgkin Lymphoma; Juvenile Polyposis; Li-Fraumeni Syndrome; Lynch Syndrome; MDS; Melanoma Syndrome; Multiple Endocrine Neoplasia Type 1; Multiple Endocrine Neoplasia Type 2; Neuroblastoma; Neurofibromatosis Type 1; Neurofibromatosis Type II; Nevoid Basal Cell Carcinoma Syndrome; Non Hodgkin Lymphoma; Noonan Syndrome and Other Rasopathy; Overgrowth Syndromes; Pancreatic Cancer; Peutz-Jeghers Syndrome; Pheochromocytoma/Paraganglioma; PTEN Hamartoma Tumor Syndrome; Retinoblastoma; Rhabdoid Tumor Predisposition Syndrome; Rhabdomyosarcoma; Rothmund-Thomson Syndrome; Tuberous Sclerosis; Von Hippel-Lindau Disease
Intervention:
Sponsor: St. Jude Children's Research Hospital
Recruiting -
Study of Biomarker-Based Treatment of Acute Myeloid Leukemia
Posted: January 9th, 2017, 3:00pm GMT
Condition: Previously Untreated Acute Myeloid Leukemia
Interventions: Biological: Samalizumab (BAML-16-001-S1); Biological: BI 836858 (BAML-16-001-S2); Other: Laboratory Biomarker Analysis; Drug: Daunorubicin (BAML-16-001-S1); Drug: Cytarabine (BAML-16-001-S1); Drug: Azacitidine (BAML-16-001-S2); Drug: AG-221 (BAML-16-001-S3); Drug: Azacitidine (BAML-16-001-S3); Drug: Entospletinib (BAML-16-001-S4); Drug: Azacitidine (BAML-16-001-S4); Drug: Entospletinib (BAML-16-001-S5); Drug: Decitabine (BAML-16-001-S5); Drug: Entospletinib (BAML-16-001-S6); Drug: Azacitidine (BAML-16-001-S6); Drug: Daunorubicin (BAML-16-001-S6); Drug: Cytarabine (BAML-16-001-S6); Drug: Pevonedistat (BAML-16-001-S9); Drug: Azacitidine (BAML-16-001-S9); Drug: AG-120 (BAML-16-001-S16); Drug: Azacitidine (BAML-16-001-S16)
Sponsor: Beat AML, LLC
Recruiting -
Assessment of Intraoperative Probe-based Confocal Laser Endomicroscopy in Digestive and Endocrine Surgery: a Pilot Study
Posted: September 16th, 2015, 2:00pm GMT
Conditions: All Surgical Conditions Usually Necessitating Frozen Section; Malignant Tumor; Inflammatory Disease; Benign Tumor
Interventions: Device: pCLE; Drug: IV fluorescein administration
Sponsor: IHU Strasbourg
Recruiting -
A Phase IV Post Approval Clinical Study of ExAblate Treatment of Metastatic Bone Tumors for the Palliation of Pain
Posted: April 17th, 2013, 2:00pm GMT
Condition: Bone Metastasis
Intervention: Device: ExAblate MRgFUS
Sponsor: InSightec
Recruiting -
European Low and Intermediate Risk Neuroblastoma Protocol
Posted: November 16th, 2012, 3:00pm GMT
Condition: LOW AND INTERMEDIATE PAEDIATRIC NEUROBLASTOMA AND NEONATAL SUPRARENAL MASSES
Intervention: Drug: chemotherapy
Sponsor: Instituto de Investigacion Sanitaria La Fe
Recruiting -
Natural History Study of Children and Adults With Medullary Thyroid Cancer
Posted: August 9th, 2012, 2:00pm GMT
Condition: Medullary Thyroid Carcer
Intervention:
Sponsor: National Cancer Institute (NCI)
Recruiting -
Study of Adrenal Gland Tumors
Posted: June 29th, 2000, 2:00pm GMT
Condition: Adrenal Gland Neoplasm
Intervention:
Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting